Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement
Fiche du document
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.leukres.2007.03.007
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/17416415
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/0145-2126
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EDE42B00030B6
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Leukaemia Leucocythemia Leucaemia Leucosis Leukosis Leucocythaemia LeucemiaCiter ce document
S. Knipp et al., « Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement », Serveur académique Lausannois, ID : 10.1016/j.leukres.2007.03.007
Métriques
Partage / Export
Résumé
We report on a 42-year-old patient whose relapse of acute promyelocytic leukaemia (APL) included meningeal infiltration. Since he had previously experienced ATRA syndrome, he received arsenic trioxide (ATO) plus intrathecal therapy with cytarabine, prednisone, and methotrexate. We measured the concentration of arsenic in his cerebrospinal fluid (CSF). Arsenic showed a peak CSF concentration of 0.008mg/l (0.11mumol/l) and a nadir of 0.002mg/l (0.027mumol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia.